The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains neutral rating for qiagen with target price of 48 dollars
UBS has maintained a "Neutral" rating for Qiagen, setting a target price of $48. Analyst Christopher Leonard noted slightly positive details following an event on the QuantiFERON blood test, which accounted for nearly 25% of the company's sales in 2024.
ubs initiates buy rating for nexans with target price of 145 euros
UBS has initiated coverage on Nexans SA with a Buy rating and a price target of €145, highlighting strong growth potential in the high voltage (HV) sector, with an expected 25% CAGR in EBITDA from 2024 to 2027. The firm anticipates that strategic divestments planned for 2025 could boost EBITDA margins from 11% to 13.5%. Analyst Christopher Leonard notes that the current market valuation underestimates the HV Transmission business, presenting an attractive opportunity for investors.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.